Paper33256166
Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2.
Hamdy R and 6 others. Int J Mol Sci, 2020. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2. Papers, record 33256166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33256166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Drug Design | Major topic |
| Oxadiazoles | Major topic |
| Proto-Oncogene Proteins c-bcl-2 | Major topic |
| Binding Sites | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Humans | |
| Inhibitory Concentration 50 | |
| Models, Molecular | |
| Protein Binding |
Source PubMed
References14
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28067996 | Virtual screening, SAR, and discovery of 5-(indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-oxadiazole as a novel Bcl-2 inhibitor. | Chem Biol Drug Des | 2017 | https://conductscience.org/library/papers/28067996 | PubMed |
| 2 | 21934653 | Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8. | Mol Ther | 2011 | https://conductscience.org/library/papers/21934653 | PubMed |
| 3 | 9703946 | Expression of Bcl-2 increases intracellular glutathione by inhibiting methionine-dependent GSH efflux. | Biochem Biophys Res Commun | 1998 | https://conductscience.org/library/papers/9703946 | PubMed |
| 4 | 19075767 | Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. | Curr Top Med Chem | 2008 | https://conductscience.org/library/papers/19075767 | PubMed |
| 5 | 28087272 | Synthesis and evaluation of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents. | Bioorg Med Chem Lett | 2017 | https://conductscience.org/library/papers/28087272 | PubMed |
| 6 | 21595920 | Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. | J Transl Med | 2011 | https://conductscience.org/library/papers/21595920 | PubMed |
| 7 | 30012635 | The rise of apoptosis: targeting apoptosis in hematologic malignancies. | Blood | 2018 | https://conductscience.org/library/papers/30012635 | PubMed |
| 8 | 18353193 | Protein-protein interactions as targets for small-molecule therapeutics in cancer. | Expert Rev Mol Med | 2008 | https://conductscience.org/library/papers/18353193 | PubMed |
| 9 | 19088047 | A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/19088047 | PubMed |
| 10 | 23474389 | Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents. | Bioorg Med Chem Lett | 2013 | https://conductscience.org/library/papers/23474389 | PubMed |
| 11 | 18645028 | Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. | Mol Cancer Ther | 2008 | https://conductscience.org/library/papers/18645028 | PubMed |
| 12 | 30986908 | New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2. | Molecules | 2019 | https://conductscience.org/library/papers/30986908 | PubMed |
| 13 | 28209992 | From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. | Nat Rev Drug Discov | 2017 | https://conductscience.org/library/papers/28209992 | PubMed |
| 14 | 19238538 | Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. | Breast Cancer Res Treat | 2010 | https://conductscience.org/library/papers/19238538 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40649366 | Hydrazides as Powerful Tools in Medicinal Chemistry: Synthesis, Reactivity, and Biological Applications. | Molecules | 2025 | https://conductscience.org/library/papers/40649366 | PubMed |
| 39313901 | Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family. | Anticancer Agents Med Chem | 2025 | https://conductscience.org/library/papers/39313901 | PubMed |
| 37834104 | Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834104 | PubMed |
| 34830153 | New Bioactive Fused Triazolothiadiazoles as Bcl-2-Targeted Anticancer Agents. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34830153 | PubMed |
| 34066442 | Synthesis and Anticancer Evaluation of New 1,3,4-Oxadiazole Derivatives. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34066442 | PubMed |
| 33924410 | Editorial for Special Issue "Bioactive Oxadiazoles". | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33924410 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| BCL2L11 | 10018 | PubTator's text mining | https://conductscience.org/library/genes/10018 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33256166
GET https://conductscience.org/api/papers/v1/33256166/authors